Drug Discovery Featured Articles & Applications

1. The 2026 Pharma R&D AI Sourcing Map: Partnerships, Concentration, Inflection 11/9/2026

   A Beroe analysis of 2026 pharma AI deals shows discovery still dominates, suppliers are consolidating, and clinical development is the next AI sourcing frontier.

2. How Peptides Are Expanding The Possibilities Of Drug Discovery 11/9/2026

   GLP-1 therapies demonstrate the impact peptide medicines have. The opportunity ahead is to extend that impact across a much broader range of biology and achieve new ways to intervene.

3. Botanical QT Risk Starts In The Extract 11/6/2026

   For a plant-derived drug candidate, the proarrhythmic liability belongs to the preparation rather than to the molecule named on the label.

4. Metabolic Interventions Improve Cancer Treatment Delivery 11/4/2026

   Could effective drug delivery depend not only on getting more therapy into a tumor but also on changing the tumor’s biological response to treatment?

5. Botanicals: Ask For Reuse, Not Relief 11/3/2026

   The FDA has a botanical drug docket open until Nov. 3, 2026, which requests information on blocks to botanical drug development, study designs, and how real-world evidence might help development.

6. Where Are Dermatology's Next Competitive Battles Taking Shape? 11/3/2026

   EADV 2026 highlighted how leaders in dermatology are looking to maintain their leadership in diseases such as PsO and AD while expanding their portfolios into smaller therapeutic areas.

7. Rewiring BCL6 To Trigger Cell Death 11/2/2026

   Shenandoah is rewiring oncogenic drivers, specifically BCL6, to bypass resistance and directly trigger the cell’s natural self-destruct machinery.

8. Built To Avoid Risk: How Industry Norms Stall Drug Discovery 10/28/2026

   At Discovery & Development US 2026 in San Diego, discovery leaders named the industry norms they would change.

9. An Incomplete Response: Will The FDA Finish What It Started With Real-Time CRLs? 10/28/2026

   FDA’s real-time CRL releases face legal and operational hurdles. Could AI-assisted redaction make transparency faster and more consistent?

10. When The Cat Is Away: The Institutional Test Of FDA Modernization 10/27/2026

    Congress has an opportunity in 2027 to restore the FDA Modernization Act 3.0's broader ambitions and establish a more accountable framework for biomedical modernization.